Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL)

Trial Profile

Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2019

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Adult T-cell leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Mar 2019 Planned primary completion date changed from 1 Nov 2021 to 1 Jan 2021.
    • 24 Jan 2019 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2021.
    • 17 Jan 2019 Planned primary completion date changed from 3 Jan 2019 to 1 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top